Article: Neurocrine Reports Positive Results for Indiplon in Adults With Transient Insomnia; Indiplon Modified Release Formulation Demonstrates Statistically Significant Improvement in Sleep Initiation.

Article: Neurocrine Reports Phase III Indiplon Results In Patients With Chronic Insomnia; Indiplon Modified Release Shows Statistically Significant Improvement In Sleep Maintenance and Sleep Quality.
PR Newswire;  September 24, 2003 ;     700+ words ......Company's first indiplon modified release Phase III clinical trial, achieving...previous clinical trials. The modified release formulation of indiplon...to this being the first Phase III outpatient study, we are...safety and efficacy of the modified ...

Article: Study demonstrates long-term efficacy with indiplon modified release.
Clinical Trials Week;  April 26, 2004 ;     495 words ......second long-term phase III trial with highly...safety of indiplon modified release in primary (chronic...other indiplon modified release studies. We are...first long-term phase III clinical trial with indiplon modified release, demonstrating...now have in ...

Article: Neurocrine Reports Two Additional Phase III Trials Demonstrating Indiplon Is Safe and Effective in Treating Elderly Patients With Difficulties Initiating and Maintaining Sleep; Results in Over 7000 Subjects to Date Support Efficacy and Safety for Sleep Initiation, Sleep Maintenance, and Long-Term Treatment.
PR Newswire;  April 7, 2004 ;     700+ words ......the Company's Phase III clinical trials...immediate release and modified release, in elderly patients...other indiplon modified release studies. The study...in-patient, out-patient Phase III clinical trial...previously conducted Phase III two-week ...

Article: Neurocrine Reports Indiplon Effective in Treating Elderly Patients With Difficulties Maintaining Sleep; Indiplon Modified Release Demonstrates Highly Statistically Significant Improvement in Sleep Maintenance.
PR Newswire;  March 2, 2004 ;     700+ words ......from its Phase III trial with the modified release formulation...indiplon modified release reflect some...these robust Phase III clinical...release and modified release are being...all of its Phase III safety and...

Article: Neurocrine Biosciences Announces Indiplon Modified Release Demonstrates Lack of Respiratory Side Effects.
PR Newswire;  May 6, 2004 ;     700+ words ......studies demonstrating that indiplon modified release does not effect respiratory functioning...crossover design with indiplon modified release 30 mg, codeine sulfate 60 mg (as...control), or placebo. Indiplon modified release demonstrated no statistically or...points. The 30 mg dose ...

Article: Neurocrine Reports Positive Phase III Efficacy and Safety Results With Indiplon Modified Release in Treating Elderly Patients.
PR Newswire;  September 9, 2004 ;     700+ words ......immediate and modified release formulations of...dose of indiplon modified release tablets demonstrated...sNAASO). Indiplon modified release tablets also demonstrated...other indiplon modified release and immediate...multi-center, out-patient Phase III ...

Article: Preliminary results reported on phase III indiplon trial.
Drug Week;  October 24, 2003 ;     528 words ......company's first indiplon modified-release, phase III clinical trial, which achieved...previous clinical trials. The modified release formulation of indiplon...addition to this being the first phase III outpatient study, we are...

Article: Neurocrine's 'SLEEP' Study Demonstrates Highly Positive Long-Term Efficacy Results With Indiplon Modified Release; Patients Gained Up to 90 Minutes of Total Sleep Time - Sustained Throughout Study.
PR Newswire;  March 24, 2004 ;     700+ words ......second long term Phase III trial with highly...Safety of indiplon modified release in Primary (Chronic...other indiplon modified release studies. We are...first long term Phase III clinical trial...multi-center, out-patient Phase III clinical trial...doses ...

Article: Positive results reported from indiplon modified release 15 mg trial in insomnia.
Biotech Week;  September 29, 2004 ;     516 words ......results from the company's phase III clinical trial with indiplon modified release 15 mg in 229 elderly patients...multi-center, out-patient phase III clinical trial conducted...administration of 15 mg of indiplon modified release tablets or placebo over...

Article: Neurocrine Biosciences initiates first efficacy and safety phase III clinical trial for Indiplon-MR.
Drug Week;  August 2, 2002 ;     284 words ......the first of three pivotal phase III clinical trials with indiplon-MR (modified release formulation of NBI-34060...schedule in a 1-year safety phase III clinical trial with indiplon-...conducting five of eight planned phase III clinical trials with indiplon...plans to ...

Article: Neurocrine Biosciences initiates first efficacy and safety phase III clinical trial for Indiplon-MR.(Brief Article)
Pain & Central Nervous System Week;  July 29, 2002 ;     288 words ......the first of three pivotal phase III clinical trials with indiplon-MR (modified release formulation of NBI-34060...schedule in a 1-year safety phase III clinical trial with indiplon-...conducting five of eight planned phase III clinical trials with indiplon...plans to ...

Article: Neurocrine Biosciences Announces Positive Phase II Efficacy and Safety Results With NBI-34060 Modified Release (MR); First Efficacy Based Trial in MR Shows Improvement in Maintaining Sleep.
PR Newswire;  January 18, 2002 ;     700+ words ......results with NBI-34060 Modified Release (MR) tablets in a Phase II study in 47 adult patients...Neurocrine expects to initiate Phase III clinical trials with NBI-3406...34060 is currently in Phase III clinical testing. Patient...prescribed hypnotics, the modified ...

Article: Data: Indiplon modified release demonstrates lack of respiratory side effects.
Respiratory Therapeutics Week;  May 31, 2004 ;     435 words ......studies demonstrating that indiplon modified release does not affect respiratory functioning...double-blind crossover design with indiplon modified release 30 mg, codeine sulfate 60 mg (as a positive control), or placebo. Indiplon modified release demonstrated no statistically or ...

Article: PIXYKINE PHASE III RESULTS IN TRANSPLANTATION SHOW BENEFIT SIMILAR TO CONTROL DRUG LEUKINE
PR Newswire;  October 26, 1995 ;     700+ words ......announced preliminary data analysis of a Phase III clinical study of the investigational...Leukine was approved in 1991 based on a Phase III study in transplant patients that showed...red blood cells. At some centers in the Phase III study, a similar improvement was noted...